Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombin...

por Plum‐Mörschel, Leona, Singh, Gursharan, Murugesan, Sundara Moorthi Nainar, Marwah, Ashwani, Panda, Jayanti, Loganathan, Subramanian, Athalye, Sandeep N.
Publicado 2022

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19

por Kumar, Suresh, De Souza, Rosemarie, Nadkar, Milind, Guleria, Randeep, Trikha, Anjan, Joshi, Shashank R., Loganathan, Subramanian, Vaidyanathan, Sivakumar, Marwah, Ashwani, Athalye, Sandeep N.
Publicado 2021

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Reco...

por Plum‐Mörschel, Leona, Klein, Oliver, Singh, Gursharan, Murugesan, Sundara Moorthi Nainar, Marwah, Ashwani, Sharma, Nirant, Panda, Jayanti, Loganathan, Subramanian, Lakshmi, Gopu Chandrasekharan, Athalye, Sandeep N.
Publicado 2022

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer

por Socinski, Mark A., Waller, Cornelius F., Idris, Tazeen, Bondarenko, Igor, Luft, Alexander, Beckmann, Katrin, Vishweswaramurthy, Ashwini, Loganathan, Subramanian, Donnelly, Charles, Hummel, Matthew A., Shapiro, Roxann, Woods, Melody, Rao, Anita, Nayak, Vivek G, Ranganna, Gopinath, Barve, Abhijit
Publicado 2021

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

por Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Waller, Cornelius F.
Publicado 2021

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

por Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Mukhametshina, Guzel, Nemsadze, Gia, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Baramidze, Kakhaber, Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Mamillapalli, Gopichand, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Fuentes-Alburo, Adolfo, Waller, Cornelius F.
Publicado 2021